Interview with Nick Coupe on the Importance of Melanoma Awareness

Dr Nick Coupe, a consultant at the Churchill hospital, has been talking to That’s TV Oxfordshire about the importance of Melanoma awareness. This May, Skin Cancer Awareness Month, we are producing a series of blogposts to highlight what’s going on in Oxford to tackle skin cancer. Skin cancer is a cancer where rates are rising, here Nick talks about what we should all look out for and the promising research emerging from leading cancer research centres such as the Oxford Cancer Network.

Watch Nick’s interview here:

Find out more about our research below

New melanoma drug a step closer to the clinic

Clinical trials into the use of Tebentafusp for metastatic uveal melanoma have been conducted by the University of Oxford and Immunocore. The positive results of the most recent trial mean this drug could now be used in future treatment.

What we can learn from cancer survivors

Understanding how an individual survives cancer, and why they respond well to therapy, can be vital in identifying new therapeutic targets. A new project seeks to see why some advanced pancreatic cancer patients overcome the odds and respond positively to treatment.

Therapeutic potential for breast cancer found in the matrix

Work currently underway in the laboratory of Prof Kim Midwood is investigating the therapeutic anti-cancer potential of tenascin-C, a molecule found in the extracellular matrix of breast cancer

The developmental origins of resistant infant leukaemia

The Roy and Milne labs are investigating the developmental origins of infant leukaemia and its influence on the biology of the disease

Epigenetic markers for melanoma patient response to ICB therapy

Development fund winners Rosalin Cooper & Ben Fairfax are investigating the epigenetic landscape of melanoma patients and how it can impact patient sensitivity to ICB therapy

New melanoma cancer drug in development shows promise

University of Oxford and Immunocore Ltd have investigated Tebentafusp, a new anti-tumor immune response drug for patients with metastatic melanoma

Researchers discover mutation that determines treatment efficiency

Weatherall Institute of Molecular Medicine researchers have recently discovered why a class of cancer drugs is beneficial only in a subset of patients

Mapping the T-cell landscape of pancreatic cancer

Through analysis of T-cell populations, researchers Drs Enas Abu-Shah & Shivan Sivakumar identify novel therapeutic opportunities in pancreatic cancer patients

Dr Eileen Parkes joins Oxford Cancer

Eileen brings research into the body’s innate immune response to cancer and how we can harness these pathways to develop novel clinical treatments